XRCC4 and ovarian carcinoma: Through an NHEJ-pathway-focused RNAi screen, we found that XRCC4 specifically sensitized cisplatin treatment in cisplatin-resistant ovarian cancer cell lines, which were further confirmed by a sgRNA-based secondary screen.